This site is intended for healthcare professionals only
DiabetesontheNet Logo
×

Learn about the practical use of Suliqua®(insulin glargine 100 units/mL and lixisenatide) for the treatment of type 2 diabetes in adults

Despite current guideline recommendations for people with type 2 diabetes,1,2 treatment often remains suboptimal, with many patients failing to achieve glycaemic targets over time.3,4 When treatment intensification with multiple therapies is required, use of combination products may simplify regimens and aid compliance.5

This website aims to provide healthcare professionals with advice and practical information about Suliqua, a once-daily, titratable, fixed-ratio combination of basal insulin glargine 100 Units/mL and the glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide. Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.6 We hope that you will find the resources on this website useful in your everyday clinical practice.

Video resources

UK healthcare professionals discuss the use of Suliqua in everyday clinical practice

Play Video

Video

48 mins

Watch the presentations from the webcast broadcast on 5 May 2021

Ed Jude, Consultant in Diabetes and Endocrinology, Tameside Hospital
NHS Foundation Trust

Grace Vanterpool, Nurse Consultant, Diabetes, West London NHS Trust

Play Video

Video

16 mins

Practical use of Suliqua for the management of people with type 2 diabetes

Amar Ali, GP, Blackburn

Play Video

Video

7 mins

Outlining the rationale for fixed ratio combination therapy

Amar Ali, GP, Blackburn

Play Video

Video

7 mins

Improving glycaemic outcomes in uncontrolled high risk type 2 diabetes: Frequently asked questions

Ed Jude, Consultant in Diabetes and Endocrinology, Tameside Hospital
NHS Foundation Trust

Play Video

Video

9 mins

Improving glycaemic outcomes in uncontrolled high risk type 2 diabetes: Frequently asked questions

Grace Vanterpool, Nurse Consultant, Diabetes, West London NHS Trust

Play Video

Video

32 mins

Watch the presentations from the webcast broadcast on 2 November 2021

Rory McCrimmon, Dean of Medicine, Professor of Experimental Diabetes and Metabolism and Honorary Consultant, Tayside, Scotland

Case studies

Examine the clinical considerations and treatment decisions for patients about to be initiated on Suliqua

Print materials

This advertorial aims to outline key aspects of the efficacy and
safety of Suliqua from the Phase III clinical trial data as well as providing practical advice on its initiation and titration.

Amar Ali, a GP with a special interest in diabetes from Blackburn, shares his own personal experience of using Suliqua in patients treated in primary care, along with hints and tips for its use in this context.

Learn more about Suliqua
For more information on Suliqua, such as patient support, dosing and titration guides, videos and further evidence

References

1. Buse JB, et al (2020) Diabetes Care 43:487–93

2. NICE (2015). Type 2 diabetes in adults: management (NG28). Available at:
https://www.nice.org.uk/guidance/ng28 (accessed January 2022)

3. Khunti K et al (2013) Diabetes Care 36:3411–7

4. Khunti K, Millar-Jones DM (2017) Prim Care Diab 11:3–12

5. Skolnik N, et al (2017) Curr Med Res Opin 33:2187–94

6. Suliqua Summary of Product Characteristics. Available at:
https://www.medicines.org.uk/emc/product/9871/smpc (accessed January 2022)

The resources on this website have been initiated and fully funded by Sanofi. They have been reviewed and approved by the sponsoring company prior to publication. Editorial support for this webinar has been provided by OmniaMed Communications.

MAT-GB-2103811 (V2.0) January 2022

For the latest news and articles

Sign up to all DiabetesontheNet journals

Resources

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.